Applications of Neoadjuvant Therapy in the Treatment of Gastrointestinal Cancers
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".
Deadline for manuscript submissions: 31 October 2024 | Viewed by 2331
Special Issue Editors
2. Morsani College of Medicine, University of South Florida, Tampa, FL, USA
Interests: gastrointestinal malignancies; precision oncology; targeted therapy; adoptive cell therapies
Special Issue Information
Dear Colleagues,
Surgery is often used to attempt to cure patients whose tumors are localized within the gastrointestinal (GI) tract. However, tumor complexity and morbidity delaying a timely return to intended oncology treatment (RIOT) are important drawbacks with upfront resection and may be associated with worse outcomes.
Neoadjuvant therapy is an attractive concept for any GI malignancy that allows us to test tumor behavior and select the right patient for a major procedure, to downsize a previously borderline or unresectable tumor, to treat micro-metastatic disease early, and to allow organ preservation.
In 1974, Dr. Norman Nigro and colleagues at Wayne State University introduced neoadjuvant chemoradiotherapy prior to abdominoperineal resection for anal cancer. They initially published a series in Diseases of the Colon and Rectum of three patients with anal squamous cell carcinoma treated with combined chemotherapy and radiation. The first two patients underwent surgical resection, and complete pathological response was seen. The third patient declined surgery and was free of recurrence after 14 months of follow-up. This combination became known as the “Nigro Protocol”, and after further study, it became the new standard of care in anal cancer.
Since Dr. Nigro’s successful experiment, several trials have demonstrated the benefits of adding preoperative chemotherapy and/or radiotherapy in the treatment landscape.
This Special Issue aims to provide a comprehensive review of neoadjuvant therapies in GI malignancies, exploring the clinical application, current evidence, and treatment prospect with this approach in different tumors.
Dr. Tiago Biachi De Castria
Dr. Natally Horvat
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neoadjuvant
- preoperative
- gastrointestinal malignancies
- chemotherapy
- radiotherapy
- radiomics
